The North West Fund for Biomedical and Fusion IP are coming together to back the growth ambition of University of Sheffield spin-out Absynth Biologics.
AIM-listed investment firm Imperial Innovations Group has secured a £30 million loan so that it can make investments in the biotech and therapeutics sectors.
A £125,000 equity investment allocation has been secured by LumbaCurve International to aid in its efforts to conduct market development and a clinical effectiveness study for its lower back pain treatment.
ADC Biotechnology has secured a package of investment and grants totalling £450,000 to expand development and commercialisation of its new antibody drug production technology.
